Eli Lilly: Short-Term Upside Exhausted (Rating Downgrade)

Discover why Eli Lilly's stock downturn may present new opportunities. Learn about valuation, Zepbound pricing, and 2026 ...
BioSpace

Lilly Cuts Zepbound Prices, Again, When Buying Through DTC Program

Following Novo Nordisk’s price cuts for its own GLP-1 medicines, Eli Lilly is offering discounts for the obesity drug ...

GLP-1 drugs have 'little or no effect' on risk of obesity-related cancers, study suggests

Doctors say the class of medications that includes Ozempic and Zepbound still offers health benefits for people with diabetes ...

Lilly Cuts Low-Dose Zepbound Price Up to 20% for Cash-Pay Buyers

Eli Lilly & Co. is cutting the price for introductory doses of its weight-loss drug Zepbound again, as competition heats up ...

Novo's Next Shot at Dominance: High-Dose Wegovy Takes Aim at Lilly's Zepbound

Regulators in Europe just backed Novo's heavyweight Wegovy--setting the stage for a head-to-head obesity drug showdown in ...
Fierce Pharma

Lilly joins Novo in GLP-1 self-pay price cuts, lowering costs of single-dose Zepbound vials

In the early November announcement of its agreement with the government, Lilly pledged to reduce the self-pay price of ...
Devdiscourse

Race in Obesity Drugs Heats Up Amidst Legal Battles and Aid Crises

Eli Lilly's new obesity drug shows promising results in weight loss, surpassing its existing drug Zepbound, as competition in ...

Eli Lilly Just Delivered Fantastic News to Investors

Eli Lilly’s weight loss drugs have delivered blockbuster sales in recent quarters. The company is a leader in this market ...